Clinical development directions in oncolytic viral therapy

被引：0
作者：
R M Eager
J Nemunaitis
机构：
[1] Mary Crowley Cancer Research Centers,Department of Internal Medicine
[2] The University of Hawaii,undefined
[3] Texas Oncology PA,undefined
[4] Medical City Dallas Hospital,undefined
来源：
Cancer Gene Therapy | 2011年 / 18卷
关键词：
oncolytic viruses; virotherapy; adenoviruses; herpes simplex virus;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Oncolytic virotherapy is an emerging experimental treatment platform for cancer therapy. Oncolytic viruses are replicative-competent viruses that are engineered to replicate selectively in cancer cells with specified oncogenic phenotypes. Multiple DNA and RNA viruses have been clinically tested in a variety of tumors. This review will provide a brief description of these novel anticancer biologics and will summarize the results of clinical investigation. To date oncolytic virotherapy has shown to be safe, and has generated clinical responses in tumors that are resistant to chemotherapy or radiotherapy. The major challenge for researchers is to maximize the efficacy of these viral therapeutics, and to establish stable systemic delivery mechanisms.
引用
收藏
页码：305 / 317
页数：12
相关论文
共 939 条
[1]  
Bischoff JR(1996)An adenovirus mutant that replicates selectively in p53-deficient human tumor cells Science 274 373-376
[2]  
Kirn DH(1997)ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents Nat Med 3 639-645
[3]  
Williams A(1999)Identification of the transcriptional regulatory sequences of human kallikrein 2 and their use in the construction of calydon virus 764, an attenuated replication competent adenovirus for prostate cancer therapy Cancer Res 59 1498-1504
[4]  
Heise C(1999)The addition of adenovirus type 5 region E3 enables calydon virus 787 to eliminate distant prostate tumor xenografts Cancer Res 59 4200-4203
[5]  
Horn S(2000)An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy Nat Med 6 1134-1139
[6]  
Muna M(1998)A novel three-pronged approach to kill cancer cells selectively: concomitant viral, double suicide gene, and radiotherapy Human Gene Ther 9 1323-1333
[7]  
Heise C(2000)A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect Oncogene 19 2-12
[8]  
Sampson-Johannes A(2000)Selectivity of a replication-competent adenovirus for human breast carcinoma cells expressing the MUC1 antigen J Clin Invest 106 763-771
[9]  
Williams A(2002)Cytosine deaminase-armed selectively-replicating adenovirus for the treatment of cancer Proc Am Assoc Cancer Res 43 3257-6155
[10]  
McCormick F(2002)Oncolytic adenoviruses dependent on two prevalent alterations in human cancer: Disregulation of the Rb-pathway and telomerase Mol Ther 5 165-1041
12345678910